The Global Parkinson's Genetics Program (GP2) is an ambitious international initiative to understand the genetic basis of Parkinson's disease through large-scale genomic studies across diverse populations. Launched in 2019 with funding from the Michael J. Fox Foundation, GP2 aims to accelerate precision medicine for PD by identifying genetic risk factors and understanding how they influence disease progression and treatment response.
Prior to GP2, the vast majority of PD genetic studies focused on populations of European ancestry, leaving significant gaps in understanding:
GP2 was launched to address these gaps through:
| Population Group | Target Samples | Status |
|---|---|---|
| European ancestry | 50,000 | Near target |
| African ancestry | 30,000 | Expanding |
| East Asian | 25,000 | Active |
| South Asian | 25,000 | Active |
| Latin American | 15,000 | Starting |
| Other/Mixed | 15,000 | Developing |
GP2 is coordinated by a steering committee:
| Region | Lead Institution | Countries Represented |
|---|---|---|
| North America | NIH, Michael J. Fox Foundation | USA, Canada |
| Europe | Wellcome Sanger Institute | UK, Germany, France |
| Latin America | University of São Paulo | Brazil, Argentina |
| Africa | University of Cape Town | South Africa, Nigeria |
| Asia | RIKEN, Seoul National University | Japan, Korea |
GP2 employs multiple complementary approaches:
Sample Collection → Genotyping/ Sequencing →
QC and Harmonization → Population-specific Analysis →
Cross-population Meta-analysis → Functional Validation →
Drug Target Identification
GP2 has contributed to identifying novel PD risk genes:
| Gene | Population | Discovery Method | Impact |
|---|---|---|---|
| GBA1 | Multiple | WES | Major risk factor |
| LRRK2 | Multiple | GWAS | Common risk |
| New loci | Diverse | GWAS meta-analysis | Novel discoveries |
| Population | Key Finding | Clinical Implication |
|---|---|---|
| East Asian | Novel risk alleles | Population-specific testing |
| African | LRRK2 variants | Genetic counseling |
| South Asian | GBA1Founder effects | Carrier screening |
GP2 is closely integrated with the NIH's AMP-PD program:
Genetic data from GP2 enables:
| Application | Example |
|---|---|
| Patient stratification | GBA carrier trials |
| Target validation | LRRK2 inhibitor trials |
| Biomarker development | Genetic progression markers |
| Precision recruitment | Genotype-specific enrollment |
GP2 provides open-access data resources:
| Tool | Purpose |
|---|---|
| GP2 Browser | Variant lookups |
| MAGMA | Gene set enrichment |
| PRSice | Polygenic risk scores |
| LDpred | PRS calculation |
GP2 findings have informed drug development programs:
| Target | Approach | Development Stage |
|---|---|---|
| LRRK2 | Kinase inhibitors | Phase II/III |
| GBA1 | Chaperone therapy | Phase I/II |
| ATP13A9 | Lysosomal function | Preclinical |
Genetic findings enable drug repurposing:
GP2 supports early-career researchers:
The program builds research capacity:
GP2 aims to enable: